BioSig Technologies advances collaboration on machine learning, AI solutions

BioSig Technologies announced that it is advancing the research and development of an artificial intelligence medical device platform in collaboration with technical advisory partner Reified Labs. The platform’s foundational machine learning model is anticipated to be based on integrated healthcare datasets, beginning with ECG and IECG data acquired by BioSig’s first product, the PURE EP Platform. Electrophysiology-focused technological solutions developed under the terms of the collaboration may be integrated into PURE EP technology for potential commercial application. “The cutting-edge work this collaboration started in early 2019 to lay a foundation in AI was ahead of the curve, and our initial findings may have several potentially valuable clinical applications worthy of further exploration,” commented Kenneth Londoner, Chairman and CEO of BioSig Technologies, Inc.